Literature DB >> 10514406

Widespread alterations of alpha-synuclein in multiple system atrophy.

D W Dickson1, W Liu, J Hardy, M Farrer, N Mehta, R Uitti, M Mark, T Zimmerman, L Golbe, J Sage, A Sima, C D'Amato, R Albin, S Gilman, S H Yen.   

Abstract

Glial cytoplasmic inclusions (GCI) are the hallmark of multiple system atrophy (MSA), a rare movement disorder frequently associated with autonomic dysfunction. In this study of 21 cases of MSA, GCI were consistently immunoreactive for alpha-synuclein and double-immunostained for ubiquitin and oligodendroglial markers, but not glial fibrillary acidic protein. No statistically significant difference was found in the density of GCI in various brain regions in the two forms of MSA, striatonigral degeneration (SND) and olivopontocerebellar atrophy (OPCA). Postmortem brain samples from 9 cases of MSA were fractionated according to solubility in buffer, Triton-X 100, sodium dodecyl sulfate (SDS), and formic acid, and alpha-synuclein immunoreactivity was measured in Western blots. Total alpha-synuclein immunoreactivity was increased in MSA compared to controls, with no statistically significant difference between SND and OPCA. Most of the increase was due to alpha-synuclein in SDS fractions. In controls this fraction had little or no immunoreactivity. In 7 cases and 4 controls correlations were investigated between quantitative neuropathology and biochemical properties of alpha-synuclein. Surprisingly, the amount of SDS-soluble alpha-synuclein correlated poorly with the number of GCI in adjacent sections. Furthermore, areas with few or no GCI unexpectedly had abundant SDS-soluble alpha-synuclein. These findings provide evidence that modifications of alpha-synuclein in MSA may be more widespread than obvious histopathology. Moreover, these alterations may constitute a biochemical signature for the synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514406      PMCID: PMC1867032          DOI: 10.1016/s0002-9440(10)65226-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease.

Authors:  N J Cairns; P F Atkinson; D P Hanger; B H Anderton; S E Daniel; P L Lantos
Journal:  Neurosci Lett       Date:  1997-07-11       Impact factor: 3.046

2.  Multiple-system atrophy: a new alpha-synuclein disease?

Authors:  W P Gai; J H Power; P C Blumbergs; W W Blessing
Journal:  Lancet       Date:  1998-08-15       Impact factor: 79.321

3.  Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.

Authors:  A Takeda; M Mallory; M Sundsmo; W Honer; L Hansen; E Masliah
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

4.  Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy.

Authors:  K Arima; M Nakamura; N Sunohara; M Ogawa; M Anno; Y Izumiyama; S Hirai; K Ikeda
Journal:  Acta Neuropathol       Date:  1997-06       Impact factor: 17.088

5.  Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990.

Authors:  J H Bower; D M Maraganore; S K McDonnell; W A Rocca
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

6.  Myelin degeneration in multiple system atrophy detected by unique antibodies.

Authors:  A Matsuo; I Akiguchi; G C Lee; E G McGeer; P L McGeer; J Kimura
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

7.  Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration.

Authors:  O Bandmann; M G Sweeney; S E Daniel; G K Wenning; N Quinn; C D Marsden; N W Wood
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

8.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

Authors:  M Baba; S Nakajo; P H Tu; T Tomita; K Nakaya; V M Lee; J Q Trojanowski; T Iwatsubo
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

9.  Multiple system atrophy: a review of 203 pathologically proven cases.

Authors:  G K Wenning; F Tison; Y Ben Shlomo; S E Daniel; N P Quinn
Journal:  Mov Disord       Date:  1997-03       Impact factor: 10.338

10.  Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy.

Authors:  K Wakabayashi; M Yoshimoto; S Tsuji; H Takahashi
Journal:  Neurosci Lett       Date:  1998-06-19       Impact factor: 3.046

View more
  70 in total

Review 1.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.

Authors:  J E Galvin; B Giasson; H I Hurtig; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  Neurodegeneration in the age of molecular biology.

Authors:  Lawrence I Golbe
Journal:  BMJ       Date:  2002-06-22

5.  Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis.

Authors:  Nozomi Hishikawa; Jun-Ichi Niwa; Manabu Doyu; Takashi Ito; Shinsuke Ishigaki; Yoshio Hashizume; Gen Sobue
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

6.  Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders.

Authors:  Thomas G Beach; Charles H Adler; Geidy Serrano; Lucia I Sue; D G Walker; Brittany N Dugger; Holly A Shill; Erika Driver-Dunckley; John N Caviness; Anthony Intorcia; Jessica Filon; Sarah Scott; Angelica Garcia; Brittany Hoffman; Christine M Belden; Kathryn J Davis; Marwan N Sabbagh
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

8.  Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway.

Authors:  Yuhe Yuan; Jin Jin; Bo Yang; Wei Zhang; Jinfeng Hu; Yun Zhang; Nai-Hong Chen
Journal:  Cell Mol Neurobiol       Date:  2007-08-22       Impact factor: 5.046

Review 9.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

10.  p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy.

Authors:  Yun Ju C Song; Ditte M S Lundvig; Yue Huang; Wei Ping Gai; Peter C Blumbergs; Peter Højrup; Daniel Otzen; Glenda M Halliday; Poul H Jensen
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.